Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials
Description
Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials
Report Scope:
This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report’s patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.
This report segments the global market into four regions
North America.
Europe.
Asia-Pacific.
Rest of the World (RoW).
Report Includes:
57 data tables and 83 additional tables
An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials
Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region
A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods
Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets
Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies
Review of the key patent grants/publications for insulin as a drug, along with its delivery methods
Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies
Profiles of the leading market players
Table of Contents
158 Pages
- Chapter 1 Introduction
- Overview
- Study Goals and Objectives
- Reasons for Doing the Study
- What's New in this Report?
- Scope of Report
- Information Sources
- Methodology
- Secondary Research
- Geographic Breakdown
- Segmentation Breakdown
- Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
- Developments and Trends
- Chapter 3 Market Overview
- Introduction
- What is Diabetes?
- Types of Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy
- Impaired Glucose Tolerance and Impaired Fasting Glucose
- Epidemiology of Diabetes
- Gender Distribution
- Regional Disparities
- Market Dynamics Snapshot
- Factors Affecting the Market
- Market Drivers
- Market Restraints
- Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type
- Overview
- Technological Advances in Insulin Syringes
- Insulin Delivery Pen Devices
- Disposable Insulin Pens
- Reusable Insulin Pens
- Technological Advances in Insulin Drug and Delivery Pen Devices
- External Insulin Pumps
- Technological Advances in Insulin Pump Systems
- Implantable Insulin Pumps
- Closed-Loop Artificial Pancreas
- Bionic Pancreas
- Smart Pens
- Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application
- Overview
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Chapter 6 Global Market for for Insulin Drug Delivery Devices, by Region
- Overview
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Chapter 7 Regulatory Landscape
- Overview
- U.S. Regulations for Insulin Drug and Delivery Technologies
- European Regulations for Insulin Drug and Delivery Technologies
- Japan's Regulations for Insulin Drug and Delivery Technologies
- China's Regulations for Insulin Drug and Delivery Technologies
- Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective
- Introduction
- ESG Performance Analysis
- Chapter 9 Emerging Technologies
- Introduction
- Patient Outcomes Beyond Glucose Control
- Chapter 10 Patent Analysis
- Overview
- Chapter 11 M&A and Venture Funding Outlook
- M&A Analysis
- Chapter 12 Competitive Landscape
- Overview
- Chapter 13 Company Profiles
- ASTRAZENECA
- B. BRAUN SE
- BD
- CARDINAL HEALTH
- DEBIOTECH SA
- DIABELOOP SA
- EMPERRA GMBH E-HEALTH TECHNOLOGIES
- EMBECTA CORP.
- F. HOFFMANN-LA ROCHE LTD.
- INSULET CORP.
- JOHNSON & JOHNSON SERVICES INC.
- LIFESCAN IP HOLDINGS LLC.
- LILLY
- MEDTRONIC
- NOVO NORDISK A/S
- NUGEN MEDICAL DEVICES
- OWEN MUMFORD LTD.
- SANOFI
- SOOIL DEVELOPMENTS CO. LTD.
- TANDEM DIABETES CARE INC.
- TERUMO CORP.
- YPSOMED AG
- Chapter 14 Appendix
- Government Regulatory Agencies and Professional Organizations
- List of References
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
